The accuracy of warfarin dosage based on VKORC1 and CYP2C9 phenotypes in a Chinese population

  • Agustinus Wijaya
  • Jiang T. Bo
  • He Jun
  • Jiang W. Ping
  • Jiang Bin
  • Chen H. Jie
  • Yang B. Wen
  • Xu M. Zhu
  • Qiu Q. Cheng
DOI: https://doi.org/10.13181/mji.v21i2.489
Keywords: CYP2C9, pharmacogenetic algorithm, VKORC1, warfarin
Abstract viewed: 595 times
PDF downloaded: 545 times

Abstract

Background: The aim of this study is to assess the accuracy of warfarin dosage based on VKORC1 and CYP2C9 genotype in Chinese population.

Methods: Blood samples were taken from 37 patients. We compared the warfarin dosage obtained from genotype (according to www.warfarindosing.org) and treatment dosage with international normalized ratio (INR) value within 2.0-3.0.

Results: The majority of Chinese people in our study are VKORC1 homozygous AA (89.2%), rarely VKORC1 heterozygous AG and we cannot find a patient with homozygous GG. For CYP2C9 genotype, most patients have the wildtype variants (CYP2C9*2 CC and CYP2C9*3 AA). The warfarin dosage for patients with VKORC1 AA and CYP2C9*3 AC is lower than for patients with other genotype variants.

Conclusion: There is no significant difference between pharmacogenetic algorithm (www.warfarindosing.org) and our treatment dosage. Our conclusion is that the pharmacogenetic algorithm is accurate to predict the warfarin dose. (Med J Indones. 2012;21:108-12)

Published
2012-05-01
How to Cite
1.
Wijaya A, Bo JT, Jun H, Ping JW, Bin J, Jie CH, Wen YB, Zhu XM, Cheng QQ. The accuracy of warfarin dosage based on VKORC1 and CYP2C9 phenotypes in a Chinese population. Med J Indones [Internet]. 2012May1 [cited 2023Jun.6];21(2):108-12. Available from: http://mji.ui.ac.id/journal/index.php/mji/article/view/489
Issue
Vol 21 No 2 (2012): May
Section
Clinical Research

Copyright (c) 2012 Agustinus Wijaya, Jiang T. Bo, He Jun, Jiang W. Ping, Jiang Bin, Chen H. Jie, Yang B. Wen, Xu M. Zhu, Qiu Q. Cheng

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Authors who publish with Medical Journal of Indonesia agree to the following terms:

  1. Authors retain copyright and grant Medical Journal of Indonesia right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial License that allows others to remix, adapt, build upon the work non-commercially with an acknowledgment of the work’s authorship and initial publication in Medical Journal of Indonesia.
  2. Authors are permitted to copy and redistribute the journal's published version of the work non-commercially (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in Medical Journal of Indonesia.